
Opinion|Videos|July 29, 2024
Healthcare Specialties Involved in Managing Patients With Chronic Spontaneous Urticaria
A panel of experts discuss the healthcare specialties that become involved in treating patients with CSU.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- Which healthcare specialties are involved in managing patients with CSU, and how can multidisciplinary care be optimized?
- What are the comorbidities that are most seen in patients with CSU, and how do these affect your management plan?
Advertisement
Related to this article

Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.

Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.

The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.

ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.

Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.

Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.

ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
3
Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts
4
UPMC Health Plan's Food as Medicine Pilot for Members With Diabetes
5


